Company Performance - Orchestra BioMed Holdings, Inc. reported a quarterly loss of $0.43 per share, which aligns with the Zacks Consensus Estimate, compared to a loss of $0.37 per share a year ago [1] - The company posted revenues of $0.25 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 67.85%, and down from $0.26 million year-over-year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2][1] Stock Movement and Outlook - Shares of Orchestra BioMed Holdings, Inc. have increased by approximately 10% since the beginning of the year, contrasting with a decline of -5.1% in the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.46 on revenues of $0.74 million, and for the current fiscal year, it is -$1.95 on revenues of $3.84 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Orchestra BioMed belongs, is currently ranked in the top 27% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]

Company Performance - Fortress Biotech reported a quarterly loss of $0.26 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.79, and an improvement from a loss of $0.53 per share a year ago, resulting in an earnings surprise of 67.09% [1] - The company posted revenues of $15.12 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 12.58%, and down from $19.95 million in the same quarter last year [2] - Fortress Biotech has surpassed consensus EPS estimates three times over the last four quarters but has not beaten consensus revenue estimates during the same period [2] Stock Performance - Fortress Biotech shares have declined approximately 20.5% since the beginning of the year, compared to a decline of 5.1% for the S&P 500 [3] - The current Zacks Rank for Fortress Biotech is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.47 on revenues of $11.84 million, while for the current fiscal year, the estimate is -$1.13 on revenues of $155.67 million [7] - The estimate revisions trend for Fortress Biotech is mixed, and changes in these estimates could occur following the recent earnings report [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Fortress Biotech belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.03%. A quarter ago, it was expected that this company would post a loss of $0.60 per share when it actually produced a loss of $0.55, delivering a surprise of 8.33%. Over the last four quarters, the company has su ...

Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 18.75%. A quarter ago, it was expected that this company would post a loss of $0.20 per share when it actually produced a loss of $0.17, delivering a surprise of 15%. Over the last four quarters, the company has surpas ...

Group 1: Earnings Performance - BioXcel Therapeutics reported a quarterly loss of $3.57 per share, which was better than the Zacks Consensus Estimate of a loss of $4.36, representing an earnings surprise of 18.12% [1] - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - The revenue for the quarter ended December 2024 was $0.37 million, exceeding the Zacks Consensus Estimate by 144%, although it was slightly down from $0.38 million a year ago [2] Group 2: Stock Performance and Outlook - BioXcel Therapeutics shares have declined approximately 63.6% since the beginning of the year, contrasting with the S&P 500's decline of 2.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is -$2.72 on revenues of $0.3 million, and for the current fiscal year, it is -$16.32 on revenues of $3.51 million [7] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which BioXcel Therapeutics belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

Group 1 - Creative Medical Technology Holdings, Inc. (CELZ) is currently outperforming its peers in the Medical sector with a year-to-date performance increase of approximately 14.3%, compared to the sector average gain of 5% [4] - CELZ has a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for CELZ's full-year earnings has increased by 9.4% over the past quarter, reflecting improving analyst sentiment [4] Group 2 - CELZ is part of the Medical - Biomedical and Genetics industry, which includes 509 stocks and currently ranks 74 in the Zacks Industry Rank [6] - The Medical - Biomedical and Genetics industry has seen an average gain of 6% year-to-date, indicating that CELZ is performing better than the industry average [6] - Another stock in the same industry, 89BIO (ETNB), has also shown strong performance with a year-to-date increase of 17% and a Zacks Rank of 2 (Buy) [5][6]

Company Performance - Gossamer Bio reported a quarterly loss of $0.15 per share, better than the Zacks Consensus Estimate of a loss of $0.17, and an improvement from a loss of $0.21 per share a year ago, representing an earnings surprise of 11.76% [1] - The company posted revenues of $9.38 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 19.63%, compared to zero revenues a year ago [2] - Gossamer Bio has surpassed consensus EPS estimates two times over the last four quarters [2] Stock Performance - Gossamer Bio shares have increased by approximately 48.1% since the beginning of the year, contrasting with a decline of 4.8% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on $5 million in revenues, and for the current fiscal year, it is -$0.70 on $23.66 million in revenues [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Gossamer Bio belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Gossamer Bio's stock performance [5]

Core Viewpoint - The market anticipates BioXcel Therapeutics, Inc. (BTAI) to report a year-over-year increase in earnings despite lower revenues for the quarter ended December 2024, with actual results being crucial for stock price movement [1][2]. Financial Expectations - The consensus EPS estimate for BioXcel Therapeutics is a loss of $4.36 per share, reflecting a year-over-year change of +64.1% [3]. - Expected revenues are projected at $0.15 million, which is a decrease of 60.5% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4]. - The Most Accurate Estimate for BioXcel is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -15.50%, suggesting a bearish sentiment among analysts [10]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with a strong predictive power for positive readings [7][8]. - BioXcel's current Zacks Rank is 2 (Buy), but the negative Earnings ESP complicates predictions for an earnings beat [11]. Historical Performance - In the last reported quarter, BioXcel was expected to post a loss of $8 per share but delivered a loss of $5.12, resulting in a surprise of +36% [12]. - Over the past four quarters, BioXcel has beaten consensus EPS estimates three times [13]. Industry Comparison - Another company in the same industry, IGM Biosciences, Inc. (IGMS), is expected to report a loss of $0.72 per share, with revenues projected at $0.53 million, down 18.5% year-over-year [17]. - IGM has an Earnings ESP of 4.55% and a Zacks Rank of 2, indicating a higher likelihood of beating consensus EPS estimates [18].

Company Overview - Auna S.A. (AUNA) is a notable stock within the Medical group, which consists of 1012 companies and is currently ranked 4 in the Zacks Sector Rank [2] - AUNA has a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] Performance Comparison - Year-to-date, AUNA has achieved a return of approximately 25.8%, significantly outperforming the Medical sector's average return of 6.9% [4] - In comparison, another Medical stock, BioMarin Pharmaceutical (BMRN), has returned 8.3% year-to-date, highlighting AUNA's superior performance [4] Industry Context - Auna S.A. operates within the Medical Services industry, which includes 59 stocks and is currently ranked 83 in the Zacks Industry Rank; this industry has seen an average gain of 4.1% this year [5] - BioMarin Pharmaceutical belongs to the Medical - Biomedical and Genetics industry, which has 510 stocks and is ranked 70, with a year-to-date increase of 7.1% [6]

Company Performance - Avidity Biosciences reported a quarterly loss of $0.80 per share, which was better than the Zacks Consensus Estimate of a loss of $0.84, and compared to a loss of $0.79 per share a year ago, indicating an earnings surprise of 4.76% [1] - The company posted revenues of $2.97 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 29.26%, and this represents an increase from revenues of $2.19 million in the same quarter last year [2] - Over the last four quarters, Avidity Biosciences has surpassed consensus EPS estimates four times, but has only topped consensus revenue estimates once [2] Stock Outlook - The immediate price movement of Avidity Biosciences' stock will depend on management's commentary during the earnings call, with shares having added about 2% since the beginning of the year, outperforming the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.76 on revenues of $2.95 million, and for the current fiscal year, it is -$3.34 on revenues of $14.48 million [7] Industry Context - Avidity Biosciences operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - The performance of Avidity Biosciences' stock may also be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]